Related Experiment Video

Updated: Jul 7, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

[Immunoinflammatory factors in unstable angina. Possibility of influence of atorvastatin]

I V Logacheva, M O Kazantseva

    Kardiologiia
    |February 12, 2008
    PubMed

    Insights

    Atorvastatin improves immune status in patients with unstable angina and hypercholesterolemia. This cholesterol-lowering drug reduces inflammatory markers like tumor necrosis factor-alpha and C-reactive protein.

    Area of Science:

    • Cardiology
    • Immunology
    • Pharmacology

    Background:

    • Ischemic heart disease, particularly unstable angina with hypercholesterolemia, is associated with immune system dysregulation.
    • Elevated C-reactive protein (CRP) and specific cytokines indicate an inflammatory state in these patients.

    Purpose of the Study:

    • To investigate the impact of atorvastatin on immune status in patients with unstable angina and hypercholesterolemia.
    • To evaluate changes in cytokine levels and immune cell function during atorvastatin therapy.

    Main Methods:

    • A study involving 101 patients with unstable angina and hypercholesterolemia, divided into standard therapy and atorvastatin groups.
    • Monitoring of immune status, including levels of tumor necrosis factor-alpha (TNFalpha), C-reactive protein (CRP), interleukin-4, and interferon gamma, before and after 6 months of atorvastatin treatment.

    Main Results:

    • Patients with unstable angina and hypercholesterolemia exhibited elevated CRP, TNFalpha, interleukin-4, and interferon gamma, alongside reduced immune cell function.
    • Atorvastatin treatment demonstrated a significant hypolipidemic effect.
    • Atorvastatin administration led to a reduction in the observed immunoinflammatory shifts.

    Conclusions:

    • Atorvastatin effectively lowers lipids in patients with acute coronary pathology.
    • Atorvastatin possesses the capability to mitigate immunoinflammatory imbalances associated with unstable angina and hypercholesterolemia.

    Related Concept Videos

    Angina II: Classification01:27

    Angina II: Classification

    Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
    Angina IV: Management01:26

    Angina IV: Management

    IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Myocarditis III: Medical Management01:14

    Myocarditis III: Medical Management

    Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
    Angina III: Clinical Manifestations and Assessment01:29

    Angina III: Clinical Manifestations and Assessment

    Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...